» Articles » PMID: 36365157

Current Applications of Plant-Based Drug Delivery Nano Systems for Leishmaniasis Treatment

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Nov 11
PMID 36365157
Authors
Affiliations
Soon will be listed here.
Abstract

is a trypanosomatid that causes leishmaniasis. It is transmitted to vertebrate hosts during the blood meal of phlebotomine sandflies. The clinical manifestations of the disease are associated with several factors, such as the Leishmania species, virulence and pathogenicity, the host-parasite relationship, and the host's immune system. Although its causative agents have been known and studied for decades, there have been few advances in the chemotherapy of leishmaniasis. The urgency of more selective and less toxic alternatives for the treatment of leishmaniasis leads to research focused on the study of new pharmaceuticals, improvement of existing drugs, and new routes of drug administration. Natural resources of plant origin are promising sources of bioactive substances, and the use of ethnopharmacology and folk medicine leads to interest in studying new medications from phytocomplexes. However, the intrinsic low water solubility of plant derivatives is an obstacle to developing a therapeutic product. Nanotechnology could help overcome these obstacles by improving the availability of common substances in water. To contribute to this scenario, this article provides a review of nanocarriers developed for delivering plant-extracted compounds to treat clinical forms of leishmaniasis and critically analyzing them and pointing out the future perspectives for their application.

Citing Articles

Zein Nanoparticles-Loaded Flavonoids-Rich Fraction from : Potential Antileishmanial Applications.

Neves M, Jesus C, de Oliveira J, Buna S, Silva L, Fraceto L Pharmaceutics. 2025; 16(12.

PMID: 39771581 PMC: 11678320. DOI: 10.3390/pharmaceutics16121603.


Brazilian Amazon Red Propolis: Leishmanicidal Activity and Chemical Composition of a New Variety of Red Propolis.

Dutra R, de Sousa Jr M, Mignoni M, de Oliveira K, Pereira E, Figueredo A Metabolites. 2023; 13(9).

PMID: 37755307 PMC: 10535413. DOI: 10.3390/metabo13091027.


Chemical Characterization and Leishmanicidal Activity In Vitro and In Silico of Natural Products Obtained from Leaves of (L.) H. Rob (Asteraceae).

Froes Y, Araujo J, Goncalves J, Oliveira M, Everton G, Mouchrek Filho V Metabolites. 2023; 13(2).

PMID: 36837904 PMC: 9967733. DOI: 10.3390/metabo13020285.

References
1.
Gillespie P, Beaumier C, Strych U, Hayward T, Hotez P, Bottazzi M . Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016; 34(26):2992-2995. DOI: 10.1016/j.vaccine.2015.12.071. View

2.
Roatt B, Cardoso J, Brito R, Coura-Vital W, de Oliveira Aguiar-Soares R, Reis A . Recent advances and new strategies on leishmaniasis treatment. Appl Microbiol Biotechnol. 2020; 104(21):8965-8977. DOI: 10.1007/s00253-020-10856-w. View

3.
Ferreira M, de Almeida Junior R, Onofre T, Casadei B, Farias K, Severino P . Annatto Oil Loaded Nanostructured Lipid Carriers: A Potential New Treatment for Cutaneous Leishmaniasis. Pharmaceutics. 2021; 13(11). PMC: 8618414. DOI: 10.3390/pharmaceutics13111912. View

4.
Carter N, Stamper B, Elbarbry F, Nguyen V, Lopez S, Kawasaki Y . Natural Products That Target the Arginase in Parasites Hold Therapeutic Promise. Microorganisms. 2021; 9(2). PMC: 7911663. DOI: 10.3390/microorganisms9020267. View

5.
Varela M, Lima M, Galuppo M, Tempone A, de Oliveira A, Lago J . New alkenyl derivative from Piper malacophyllum and analogues: Antiparasitic activity against Trypanosoma cruzi and Leishmania infantum. Chem Biol Drug Des. 2017; 90(5):1007-1011. DOI: 10.1111/cbdd.12986. View